Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition

Clinical Neuropharmacology

Volumn 26, Issue 4, 2003, Pages 213-217

  Cattaneo, Carlo ^a   Caccia, Carla ^a   Marzo, Antonio ^b   Maj, Roberto ^a   Fariello, Ruggero G ^a  

^a Newron Pharmaceuticals SpA   (Italy)

^b IPAS   (United States)

Author keywords

Monoamine oxidase; Safinamide; Tyramine

Indexed keywords

CALCIUM CHANNEL; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; SAFINAMIDE; SODIUM CHANNEL; TYRAMINE;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROPHARMACOLOGY; NEUROPROTECTION; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADULT; ALANINE; ANALYSIS OF VARIANCE; BENZYLAMINES; BLOOD PRESSURE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PRESSORECEPTORS; TYRAMINE;

EID: 0041633741     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200307000-00012     Document Type: Article

References (25)

1. Salvati P, Maj R, Caccia C, et al. Biochemical and electrophysiological studies on the mechanisms of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther. 1999;288: 1151-1159.
2. Johnston JP. Some observation upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968;17:1285-1297.
3. Fowler CJ, Ross SB. Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological and clinical properties. Med Res Rev. 1984;4:323-358.
4. Hinze C, Kaschube M, Hardenberg J. Pharmacodynamics of MDL 72974A: absence of effect on the pressor response to oral tyramine. J Neurol Transm. 1994;41:371-375.
5. Walker SE, Shulman KI, Tailor SAN, et al. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol. 1996;16:383-388.
6. Bieck PD, Antonin KH. Tyramine potentiation during treatment with MAO inhibitors; brofaromine and moclobemide vs irreversible inhibitors. J Neurol Transm. 1989;28:21-31.
7. Simpson GM, Gratz SS. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. Clin Pharmacol Ther. 1992;52:286-291.
8. Colombo F, Sega R, Mailland F, et al. Beta-blockade antagonism of tyramine-induced rise in blood pressure. Eur J Clin Pharmacol. 1988;34:263-266.
9. Wilkins MR, Wynne RD, Kendall MJ. A placebo controlled comparison of the effects of pirenzepine and amitriptyline on the tyramine pressor test in healthy volunteers. Br J Clin Pharmacol. 1985; 19:829-831.
10. Reimann IW, Firkusny L, Antonin KH, et al. Intravenous amine pressor tests in healthy volunteers. Within- and between subject variances and sex differences. Eur J Clin Pharmacol. 1992;42:137-141.
11. Cusson JR, Goldenberg E, Larochelle P. Effect of a novel monoamine-oxidase inhibitor, moclobemide, on the sensitivity to intravenous tyramine and norepinephrine in humans. J Clin Pharmacol. 1991;31:462-467.
12. Pace DG, Reele SB, Rozik LM, et al. Evaluation of methods of administering tyramine to raise systolic blood pressure. Clin Pharmacol Ther. 1988;44:137-144.
13. Youdim MH, Finberg JPM. New directions in monoamine oxidase A and B selective inhibitors and substrates. Biochem Pharmacol. 1991;41:155-162.
14. Caccia C, Tocchetti P, Dal Bo L, et al. Safinamide (NW-1015): Effects on Platelets MAO-B Activity in Healthy Volunteers. Presented at the 5th International Conference on Progress in Alzheimer's and Parkinson's Disease. Kyoto, Japan. March 31-April 5 2001.
15. Ito D, Amano T, Sato H, et al. Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease. J Neurol. 2001;248:33-34.
16. Hinds NP, Hiller CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247:811.
17. Montastruc JL, Chaumerliac C, Desboeuf K, et al. Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin Neuropharmacol. 2000;23:271-275.
18. Rose LM, Ohlinger MJ, Mauro VF. A hypertensive reaction induced by concurrent use of selegiline and dopamine. Ann Pharmacother. 2000;34:1020-1024.
19. Reynolds GP, Elsworth JD, Blau K, et al. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol. 1978;6:542-544.
20. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321: 1364-1371.
21. Lees AJ, on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ. 1995;311:1602-1607.
22. Reynolds GP, Riederer P, Sandler M, et al. Amphetamine and 2-phenylethylamine in post mortem parkinsonian brain after deprenyl administration. J Neural Transm. 1978;43:271-277.
23. Larsen JP, Boas J, Erdal JE. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish study group. Eur J Neurol. 1999;6:539-547.
24. Donnan PT, Steinke DT, Stubbings C, et al. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology. 2000;55:1785-1789.
25. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomised placebo-controlled extension of the deprenyl and tocopherol anti-oxidative therapy of parkinsonism trial. Ann Neurol. 2002;51:604-612.